SEDPARK1: Safety and Efficacy Study With the Non-ergot Dopamine-agonist Piribedil in Parkinson's Disease

Desitin Arzneimittel GmbH250 enrolled

Overview

The aim of the non-interventional Post Marketing Study is to investigate the use of the non-ergot dopamine agonist piribedil (trade name: CLARIUM) in mono- and combination therapy in patients with Morbus Parkinson. Tolerability and course of the disease or change of parkinsonian symptoms during stabilisation on, or change over from other dopamine agonists will be documented under routine conditions. Piribedil should be prescribed according to its marketing authorisation by the responsible neurologist.

Study Type

OBSERVATIONAL

Enrollment

250

Conditions

Parkinson's Disease

Interventions

PiribedilDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male and female patients 18 years and older. * Indication: Morbus Parkinson. * Treatment with piribedil for the first time. * Monotherapy with piribedil. * Combination therapy with L-Dopa (from the beginning or secondary) and/or in combination with other antiparkinsonian drugs. Exclusion Criteria:

Outcomes

Primary Outcomes

to monitor use in real practice including adverse events on piribedil

Time frame: 3 months

Secondary Outcomes

Efficacy

Time frame: 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.